healthy adult males and females
Conditions
Interventions
Orally administration of TAS5315 (1mg) and Itraconazole (200mg)
Sponsors
Nasermoaddeli Ali
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Aged 18 or older and younger than 40 years at the time of consent 2) Weigh at least 45.0 kg at the time of screening tests with a body mass index (BMI, weight [kg]/[height {m}]2) ranging from 18.0 to < 25.0 kg/m2 3) Blood pressure and body temperature obtained in screening tests within the following ranges a Systolic blood pressure (in supine position), 90 to 139 mmHg b Diastolic blood pressure (in supine position), 40 to 89 mmHg c Body temperature ranging from 35.0 to 37.4 4) Judged to be healthy by the investigator based on the examination findings (subjective symptoms and objective findings), blood pressure, pulse rate, body temperature, 12-lead ECG, and laboratory tests (hematology test, biochemistry test, and urinalysis) at the time of screening tests
Exclusion criteria
Exclusion criteria: 1) Had any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded) 2) Had any severe disease history that may recur during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum observed plasma concentration (Cmax) of TAS5315, area under the plasma concentration-time curve from the time of dosing to the time of last quantifiable plasma concentration (AUClast) of TAS5315, area under the plasma concentration-time curve from the time of dosing extrapolated to infinity (AUCinf) of TAS5315 | — |
Contacts
Public ContactKotaro Suto
Taiho Pharmaceutical Co., Ltd.
Outcome results
None listed